Amyotrophic Lateral Sclerosis Pipeline Analysis 2017 by P&S Market Research

The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 69 drug candidates, of which one drug candidate is in Phase III stage, 16 drug candidates are in Phase II stage, nine drug candidates are in Phase I stage, 32 drug candidates are in Pre-Clinical stage, five candidates are inactive and six drug candidates are in discontinued stage. Amyotrophic lateral sclerosis is a neurodegenerative disorder in brain and spinal cord, the progression of the disease can further lead to muscles getting enough nourishments, which can further cause atrophy of the muscles. Amyotrophic Lateral Sclerosis occurs mostly in the lateral region of the body, in which spinal cord reflexes are too intense. This can also lead to scarring and hardening of the muscles into that region. Various new therapies and advanced technologies are driving the growth of Amyotrophic lateral sclerosis pipeline.

Explore Report Overview at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis

Insights on pipeline segments

As per the findings of the research, around 31.0% of drug candidates for the treatment of amyotrophic lateral sclerosis pipeline are being developed to be administered by oral route, 4.0% by intravenous route, 48.0% are not disclosed and 17.0% are to be administered by other routes which includes subcutaneous, intraperitoneal, sublingual, inhalation and intramuscular.

Major companies collaborate for the development of Amyotrophic Lateral Sclerosis Pipeline

The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan. Dainippon Sumitomo Pharma Co., Ltd. received exclusive research, development and commercial rights in Japan for EPI-743 and EPI-589. Edison Pharmaceuticals, Inc. received $35.0 million in an upfront payment and $15.0 million as research and development support fee. In addition, Edison Pharmaceuticals, Inc. also received $10.0 to $35.0 million in milestone payments per indication associated with successful development. After the launch, Edison Pharmaceuticals, Inc. received royalties based on sales amounts and up to $460.0 million in milestone payments in accordance with sales goals.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis/report-sample

Many companies are developing Amyotrophic lateral sclerosis drug candidates in different phases. Cytokinetics, Inc., AB Science, F. Hoffman La-Roche AG, FlexPharma, Inc., Orion Corporation, Omeros Corporation, Genervon Biopharmaceuticals, LLC, Edison Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and various other companies have their Amyotrophic lateral sclerosis drug candidates in different stages of development. Cytokinetics, Inc. has drug candidate in Phase III clinical stage.

Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, Orphazyme ApS, Edison Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and Cytokinetics, Inc.

Global Helicopter Market Size, Share, Development, Growth and Demand Forecast to 2023

According to the study, the global helicopter market is likely to grow at a CAGR of 3.4% during 2017 – 2023. Technological advancements, ageing helicopter fleet, and increasing usage of helicopters in disaster relief are driving the global helicopter market. The market is further expected to gain revenue due to the increasing customer compliance for more equipped and sophisticated avionics and flight safety. Although, there has been a drop in the number of new fleet during 2013 – 2016, increased demand from developing nations would create ample opportunities for the global helicopter manufacturers.

Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/helicopters-market

Insights on market segments

As per the findings of research, military helicopter held the larger share in the global helicopter market in 2016, primarily due to high value to volume ratio and increased demand from emerging economies in Asia-Pacific and increased need for advanced defense equipment. Civil helicopters market is expected to witness higher growth during 2017 – 2023. The highest growth of civil helicopter is attributed to the increasing demand in law enforcement, tourism, medical services, general utility and firefighting. However, the ongoing crisis in the oil and gas industry may lead to slower adoption of new fleet, especially large and heavy helicopters.

North America stands as the largest helicopter market

Geographically, North America has been the largest market for helicopter, with the U.S. being the larger contributor to the regional market, compared to Canada. Retirement of old generation helicopters is expected to create opportunities for the North American helicopter market. Majority of operators in North America are planning to increase the use of helicopters, especially civil helicopters; leading to a steady growth of the market in the region. The emerging economies of Latin America and Asia-Pacific, especially Brazil, China and India, are expected to witness high demand for civil helicopters for various applications such as law enforcement, tourism, medical services, general utility and firefighting. Latin American civil helicopter market is expected to witness the highest growth during 2017 - 2023.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/helicopters-market/report-sample

Key players focusing on the development of medium helicopters

The global helicopter manufacturers are actively involved in the development of medium helicopters for civil or military purpose with increased focus on security and technology. Operators are specifically showing interest in intermediate and medium civil helicopters in law enforcement, firefighting, and medical services. The global market especially Asia-Pacific and Latin American market exhibit strong purchase intentions for intermediate and medium helicopters. Therefore, helicopter manufacturers are focusing on the medium civil helicopter segment to increase their revenues. In March 2015, Airbus Helicopters introduced H160, a twin-engine medium class helicopter. The company claimed that the H160 represents its strategy to provide the efficient solutions for its customers to safely carry passengers in the demanding environments.

Some of the other key players in the market include Bell Helicopter Textron Inc., Korea Aerospace Industries, Ltd., Airbus SE, Russian Helicopters, Leonardo S.p.A., The Boeing Company, Lockheed Martin Corporation, Robinson Helicopter Company, Hindustan Aeronautics Limited, MD Helicopters, Inc., and Kaman Corporation.

Microfluidic Devices Market Size, Share, Development and Forecast to 2020

Microfluidic devices market is gaining significant importance due to growing R&D investment in life sciences, pharmaceuticals, and increasing point of care testing demand. The global market for microfluidic devices is expected to grow at a CAGR of 23.0% during the period 2015 to 2020 to reach $6,471 million by 2020. The factors driving the growth of microfluidic devices market are increase in demand for point of care testing products, rise in the commercial and analytical applications of these devices, and use of microfluidic products for miniaturization of chip.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/microfluidic-devices-market

Continuous innovations in microfluidic devices have led to transformation of drug discovery and development, gene expression analysis and genotyping in the pharmaceutical and biopharmaceutical industry. Microfluidic device companies are entering in collaborations and partnerships to build innovative approaches, offering advanced tools for diagnostics and research. But regulatory issues act as hindrance in the development of microfluidic devices market. Apart from regulatory challenges, the market also confronts issues from surface chemistry and geometrical problem during manufacturing process.

On the basis of application, point of care testing (POCT) is by far the fastest growing application area of microfluidic devices. The growth of application of microfluidic devices in POCT is expected to witness a CAGR of 28.2% during the period 2015 to 2020, to reach $1.8 billion in 2020. An increase in point of care testing, as an effective method for delivery of treatment, has also led to increase in demand for the microfluidic devices in the global market. Diagnostic companies are getting access to microfluidic based technologies through acquisitions, as it reduces the technology development risk and increases the reactivity.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/microfluidic-devices-market/report-sample

The major companies operating in the microfluidic devices market include Abbott Laboratories, Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc. Cepheid, Dolomite Centre, F. Hoffmann-La Roche, Fluidigm Corporation, Johnson & Johnson, Micronit Microfluidics, RainDance Technologies, Inc., and Siemens Healthcare, Inc.

Image Guided Surgery Devices Market Size, Share, Development and Demand Forecast to 2023

According to the study, the global image guided surgery devices market is likely to grow significantly during the forecast period, due to increasing prevalence of chronic diseases, and cancer, rising geriatric population and increasing cases of neurological disorders. In addition to these factors, rising healthcare expenditure and technological advancements in medical imaging also contributes to the growth of the overall market. High cost of imaging techniques and stringent regulatory requirements are some of the key factors restraining the global market growth.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/image-guided-surgery-devices-market

Insights on market segments

As per the findings of the research, the CT is the largest segment, based on device type, in the global image guided surgery devices market. CT is a non-invasive, accurate and fast diagnostic imaging test. It uses x-ray equipment to produce 3D images by taking series of images from different angles. Each image created during the CT procedure shows the bones, tissues and organs in a thin “slice” of the body.

It provides cross-sectional images generated during the CT scan and can be reformatted in multiple planes. It is used for diagnosing skeletal abnormalities, blood clots, blood vessel aneurysm and cancer. Neurology has been the largest application area for image guided surgery devices, followed by orthopedic surgery, ENT surgery, oncology surgery and others.

North America stands as the largest image guided surgery devices market

Geographically, North America has been the largest market for image guided surgery devices, with the U.S. being the larger contributor to the regional market. Increasing prevalence of neurological disorders, rising geriatric population and adoption of technological advanced imaging techniques are some of the factors that have been driving the growth of the North America image guided surgery devices market. The U.K. has been the largest contributor to the European market for image guided surgery devices, followed by Germany and France. The market is expected to witness the fastest growth in Asia-Pacific, during 2017 - 2023, owing to increasing cases of cancer, arthritis, neurological disorders and rising geriatric population.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/image-guided-surgery-devices-market/report-sample

Key players in the image guided surgery devices market

Some of the key players in the global image guided surgery devices market include Siemens AG, GE Healthcare, Koninklijke Philips N.V., Canon Inc., Hitachi, Ltd., KARL STORZ GmbH & Co. KG., Medtronic, Inc., St. Jude Medical, Inc., Varian Medical Systems, Inc., Smith & Nephew plc, Integra LifeSciences Corporation and Zimmer Holdings, Inc.

Global Nuclear Imaging Equipment Market Size, Share, Development and Demand Forecast to 2023

According to the study, the global nuclear imaging equipment market is likely to grow significantly during the forecast period, due to rising prevalence of cancer and cardiovascular diseases, increasing geriatric population and increasing prevalence of neurological disorders. In addition, rising healthcare expenditure and launch of technologically advanced products contribute to the growth of the overall market. High cost of imaging techniques is the key factor restraining the global market growth.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/nuclear-imaging-equipment-market

Insights on market segments

As per the findings of the research, based on products, the SPECT is the largest category, in the global nuclear imaging equipment market. Hybrid SPECT, further forms the larger part of the global market for SPECT. Oncology has been the largest application of the global market, followed by cardiology, neurology and others. Hospitals has been the largest end user of nuclear imaging equipment, followed by diagnostic centers, research institutes and others.

North America stands as the largest nuclear imaging equipment market

Geographically, North America has been the largest market for nuclear imaging equipment, with the U.S. being the largest contributor to the regional market. Increasing prevalence of cancer and cardiovascular diseases and presence of technological advanced products has been driving the growth of the North American market for nuclear imaging equipment. In Europe, Germany has been the largest contributor to the market for nuclear imaging equipment, followed by France and the U.K. The market is expected to witness the fastest growth in Asia-Pacific, during 2017 - 2023, owing to increasing cases of cancer, cardiovascular diseases, neurological disorders and increasing geriatric population.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/nuclear-imaging-equipment-market/report-sample

Key players in the nuclear imaging equipment market

Some of the key players in the global nuclear imaging equipment market include Siemens AG, GE Healthcare, Philips Healthcare, Digirad Corporation and Neusoft Medical Systems Co., Ltd., Cannon Inc., DDD Diagnostics, CMR Naviscan Corporation, SurgicEye GmbH and Mediso Medical Imaging Systems Ltd.

Global T-Cell Immunotherapy Pipeline Analysis, 2016

The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates, of which 16 are in Phase II stage of development. The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer. It is gaining huge traction globally, for its several advantages over conventional therapies such as very low or no side effects and high specificity.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis

Insights on pipeline segments

As per the findings of research, it was found that around 22% T-cell immunotherapeutic candidate target CD19, and 6% target Prostate Specific Membrane Antigen (PSMA) and Prostate Stem Cell Antigen(PSCA). Around 62% pipeline therapeutic candidates of T-cell immunotherapy are being administered by intravenous route, 19% drugs are administered by parenteral route, 15% therapeutic candidates are administered by infusion route.

Chimeric antigen receptors (CAR) T-cell is majorly researched and developed, representing 75% T-cell immunotherapeutic candidates

CAR T-cells are the modified T-cells used to express CARs, which recognize specific antigens present on targeted cell. CARs are specifically designed synthetic receptors, linked with the single-chain variable fragment (scFV) of a monoclonal antibody. The domain includes T-cell receptor CD3-zeta chain, which graft specificity into an immune effector cell. It mediates T-cell cytotoxicity and activation when bound to a target cell.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis/report-sample

Strategic collaborations for the development of T-cell immunotherapeutic

The research finds that the different companies are collaborating for the development of T-cell immunotherapeutic. In June 2015, Celgene Corporation and Juno Therapeutics, Inc. collaborated for the development and commercialization of immunotherapies. The two companies will leverage T-cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on CAR T and TCR technologies. Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc., Juno Therapeutics, Inc., Gradalis, Inc., Atara Biotherapeutics, Inc., Adaptimmune Therapeutics Plc., Immunocore Limited, and Lion Biotechnologies, Inc.

Alzheimer’s Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Collaboration, and Other Developments

The study analyzed that the Alzheimer's disease pipeline comprises 89 drug candidates, of which 17 products are in Phase III, 28 products are in Phase II, 28 products are in Phase I, 15 products are in Pre-Clinical stage and one product is in Discovery stage. Alzheimer’s disease is a common type of dementia and a fatal illness. It includes memory loss and loss of other intellectual abilities, which results in serious interference with the patient’s daily activities. Around 60% to 80% of dementia cases turn out to be Alzheimer’s disease and can cause problems with behavior, thinking and memory. Symptoms usually develop at a slower rate initially and becoming worse with time. Invasion of combination therapies, such as AVP-786, combination of deuterium modified dextromethorphan and ultra-low dose quinidine and use of various targets including amyloid- beta protein, tau protein is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis

Insights on pipeline segments

As per the findings of the research, around 48.0% active drug candidates of Alzheimer’s disease pipeline are being developed to be administered by oral route, 8.0% by intravenous route, 6.0% are being developed to be administered by subcutaneous route, 3.0% are being developed to be administered by parenteral route and 6.0% are being developed to be administered by other routes which include intranasal, inhalation and intravenous or subcutaneous. Most of the drug candidates are being developed to be administered by oral route, due to high patient compliance. Route of administration of around 29.0% active drug candidates of Alzheimer’s disease pipeline are not disclosed.

Several companies are involved in the development of Alzheimer’s disease pipeline, with their products in different phases. Genentech, Inc., Eisai Co., Ltd. and AstraZeneca plc, each have their drug candidates in Phase III stage of development. Eli Lilly and Company is developing six products, out of which five are in Phase I and one is in Phase II stage.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/alzheimers-disease-pipeline-analysis/report-sample

Major companies collaborate for the development of Alzheimer’s disease pipeline

The research finds that different companies have collaborated for the development of Alzheimer’s disease pipeline. In March 2014, Eisai Co., Ltd. and Biogen Idec collaborated to develop and commercialize two of Eisai's clinical candidates, E2609 and BAN2401, for Alzheimer’s disease. Also, in April 2009, Bristol-Myers Squibb Company entered an agreement with Otsuka Pharmaceutical Co., Ltd. to extend the U.S. portion of the companies’ long-standing agreement for the development and commercialization of ABILIFY (aripiprazole).

Some of the key players developing drugs for Alzheimer’s disease are Eli Lilly and Company, Genentech, Inc., Eisai Co., Ltd., Bristol-Myers Squibb Company, Biogen Idec, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Novartis Pharmaceuticals Corporation, AC Immune SA, Heptares Therapeutics and Probiodrug AG.